Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 11/20 | 0.54 |
| ▸ | AURKA | O14965 | 1/20 | 0.51 |
| ▸ | STK17A | Q9UEE5 | 3/20 | 0.48 |
| ▸ | MYLK4 | Q86YV6 | 2/20 | 0.47 |
| ▸ | NEK3 | P51956 | 1/20 | 0.47 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.47 |
| ▸ | NEK5 | Q6P3R8 | 1/20 | 0.47 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.47 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.45 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.45 |
| ▸ | RAF1 | P04049 | 1/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1633534 | 0.88 | AURKA (0.56) | BRAFAURKASTK17AMYLK4NEK3 | |
| SCHEMBL1864706 | 0.85 | BRAF (0.49) | BRAFAURKASTK17AMYLK4NEK3 | |
| SCHEMBL3319061 | 0.83 | STK17A (0.55) | BRAFAURKASTK17AMYLK4NEK3 | |
| SCHEMBL14146531 | 0.79 | STK17A (0.56) | BRAFAURKASTK17AMYLK4NEK3 | |
| SCHEMBL12671670 | 0.78 | STK17A (0.55) | BRAFAURKASTK17AMYLK4NEK3 | |
| SCHEMBL1571344 | 0.78 | IKBKB (0.54) | BRAF | |
| SCHEMBL13362845 | 0.78 | STK17A (0.55) | BRAFAURKASTK17AMYLK4NEK3 | |
| SCHEMBL1866700 | 0.78 | LRRK2 (0.48) | BRAFAURKASTK17AMYLK4NEK3 | |
| SCHEMBL13251933 | 0.77 | BRAF (0.44) | BRAFCHEK1NTRK2 | |
| SCHEMBL1864478 | 0.76 | STK17A (0.53) | BRAFAURKASTK17AMYLK4NEK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) | 2010-02-25 | — | — | US | disclosed |
| EP-2004615-A2 | QUINAZOLINES FOR PDK1 INHIBITION | Novartis AG (CH) | 2008-12-24 | — | — | EP | disclosed |
| WO-2007117607-A9 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2008-03-06 | — | — | WO | disclosed |
| WO-2007117607-A2 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS AG (CH) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | PDK1, PDK2, PDK3 | BRAF 334/4885AURKA 576/4885STK17A 86/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.